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Abstract
The indicating FTA elute micro card™ has been developed
to collect and stabilize the nucleic acid in biological samples
and is widely used in human and veterinary medicine and
other disciplines. This card is not recommended for protein
analyses, since surface treatment may denature proteins.
We studied the ability to analyse proteins in human plasma
and vaginal fluid as applied to the indicating FTA elute
micro card™ using the sensitive proximity extension assay
(PEA). Among 92 proteins in the Proseek Multiplex
Oncology Iv2 panel, 87 were above the limit of detection
(LOD) in liquid plasma and 56 among 92 above LOD in
plasma applied to FTA cards. Washing and protein elution
protocols were compared to identify an optimal method.
Liquid-based cytology samples showed a lower number of
proteins above LOD than FTA cards with vaginal fluid
samples applied. Our results demonstrate that samples
applied to the indicating FTA elute micro card™ are
amendable to protein analyses, given that a sensitive
protein detection assay is used. The results imply that
biological samples applied to FTA cards can be used for
DNA, RNA and protein detection.
Keywords FTA Elute Card, Vaginal Fluid, Plasma, Prox‐
imity Extension Assay
1. Introduction
A number of sampling devices have been developed to
collect  blood  or  plasma/serum  for  protein  analyses,
ranging from solid phase  matrices  to  the  recent  use  of
nanocapillary  technology  [1].  The  collection  of  blood
spots,  buccal  cells  and saliva  on  filter  paper  is  a  com‐
mon  sampling  method,  used  for  the  screening  of
newborns for inherited diseases, in forensic medicine and
for many other purposes. Specific surface treatments have
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been  developed  to  stabilize  nucleic  acids  applied  onto
filter  paper.  Whatman FTA technology  consists  of  two
distinct chemistries, both of which have the ability to lyse
cells on contact, denature proteins and protect DNA and
RNA  from  degradation.  The  FTA  elute  card™  (GE
Healthcare, United Kingdom) contains a chaotropic salt
and proteins remain tightly bound while DNA is eluted
from the matrix. The indicating FTA elute micro card™
also includes a purple dye that turns white when a clear
sample  is  applied.  This  colour  change  is  useful  for
verifying that the biological sample has been deposited
on the card surface, specifically when the card is used for
self-collection of samples. The indicating FTA elute micro
card™ allows for a simple elution of DNA and RNA from
the  surface  of  the  card,  and  is  extremely  suitable  for
genotyping,  sequencing and real-time PCR applications
[2, 3].
The indicating FTA elute micro card™ is presently used for
the self-collection of cervico-vaginal fluid (CVF) samples in
cervical cancer screening programmes [4-10]. It will
therefore be of interest to determine if samples collected
onto the FTA card™ can also be used for analyses of protein
biomarkers. The FTA elute card is not recommended for
protein analyses, since surface treatment may denature
proteins and to the best of our knowledge, no study has
been performed to determine whether proteins applied to
the FTA elute micro card™ can be detected. The aim of this
study was to examine the potential for using the indicating
FTA elute micro card™ for protein analyses by employing
the very sensitive and highly specific protein extension
assay (PEA) [11, 12]. PEA is based on the use of two
antibodies towards the target protein, providing high
specificity. Each antibody has a DNA tail attached and if
the DNA tails on the two antibodies are within reach of each
other, they can act as a substrate for DNA polymerase.
Protein detection is achieved through a real-time PCR,
resulting in high analytical sensitivity. The PEA has
previously been used to measure protein in biomarker
studies [13, 14]. If protein detection is indicated as feasible
in samples applied to the indicating FTA elute micro
card™, it will offer a quick, cost-effective, easy-to-store
option for sample collection, both for diagnostic purposes
and population screening.
2. Samples and Methods
2.1 Samples and preparation
CVF samples were collected from women participating in
the organized cervical cancer screening using the Rover
Viba brush (Rover Medical Devices B.V., Oss, The Nether‐
lands) and applied to the indicating FTA elute micro card™
as described earlier [15].
All FTA card samples were selected from HPV-negative
women. One sample, which had been stored for two weeks,
was selected for a first buffer-test. Twenty-eight CVF
samples were gathered representing a storage time on the
card of 1-29 months prior to analysis. Twelve samples had
been stored for one month, six samples for seven months,
six samples for 19 months and four samples were stored for
29 months. Five additional samples, with storage times of
less than two weeks, were selected for the testing protocols
for washing.
Plasma samples were obtained from five women. For each
woman, 10 μl plasma aliquots were applied to an indicating
FTA elute micro card™; the card surfaces were dried and
stored at room temperature for either 24 h or 72 h. All
samples applied to the FTA cards were processed using the
3 mm Ø Harris micro punch (Whatman, Inc., Clifton, NJ)
for collecting punches as previously described [15]. The
following washing procedures were compared: I) no wash
prior to elution; II) 1 x 5 min. wash in 100 μl water; III) 2 x
5 min. wash in 100 μl water. Proteins were eluted from the
indicating FTA elute micro card™ by placing the punch in
either a 20 μl Radioimmunoprecipitation assay buffer
(RIPA) or 20 μl Phosphate-buffered saline (PBS)-Tween 20
(0.05 %) buffer for 60 to 90 minutes.
We also investigated samples from 28 women that were
collected using the procedure applied in liquid-based
cytology. These samples were collected using a cytobrush
and dissolved in a 20 ml ThinPrep storage solution (Holo‐
gic, Inc. San Diego, USA), and stored at room temperature
for 3-10 days prior to freezing. From this solution, 1 μl was
used for the PEA analysis.
2.2 Protein analysis
One μl of either liquid plasma, elution from FTA card, or
liquid-based cytology sample was analysed using the
proximity extension assay (PEA) and the Proseek Multiplex
Oncology I v2 panel (Olink Bioscience AB, Uppsala,
Sweden). This panel includes 92 proteins selected on the
basis of their reported associations with cancer. The protein
analysis is reported as normalized protein expression levels
(NPX), which are Ct values normalized by the subtraction
of values for extension control, as well as an interplate
control; the scale is shifted using a correction factor (normal
background noise) and reported in Log 2 scale. All assay
characteristics including detection limits and measure‐
ments of assay performance and validations are available
from the manufacturer's webpage (http://www.olink.com/
products/proseek-multiplex/downloads/).
2.3 Statistical analysis
All analyses and illustrations were performed in R [16].
Spearman correlations were used throughout. The signifi‐
cance of differences in distributions was calculated using
the double-sided Wilcoxon signed-rank test. Resulting P-
values were corrected for multiple testing using either
Bonferroni or FDR correction and considered significant if
the q-value < 0.05. Linear modelling for estimating the
correlation between the NPX measurement and storage
time was performed with the lm function and the ANOVA
function.
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3. Results
3.1 Elution buffer optimization
We first compared two elution buffers, PBS-Tween 20 (0.05
%) and RIPA, for their efficiency in terms of recovering
proteins from the indicating FTA elute micro card™. A
single punch from one FTA sample was eluted in 20 μl PBS-
Tween 20 (0.05 %) or RIPA buffer and analysed using the
Proseek Multiplex Oncology I v2 panel. For both buffers,
80 of the 92 proteins in the panel had levels above the assay
background (Spearman’s rho, R2=0.92, p-value < 2.2e-16)
(Figure 1). With a cut-off of >1 NPX above background, the
PBS-Tween 20 buffer resulted in the detection of 43 proteins
and the RIPA buffer in 33 proteins. Additionally, 60
proteins showed higher NPX values for the sample FTA
elution card than a blank FTA elution card for PBS-Tween
20 buffer and 52 proteins for the sample eluted in RIPA
buffer. Thus, the PBS-Tween 20 buffer performed better
than the RIPA buffer and was therefore used in the
following analyses.
Figure 1. Comparison of the NPX values for the 92 proteins in the Proseek
Multiplex Oncology Iv2 panel from analysis of a sample applied to the
indicating FTA elute micro card™ and eluted with either RIPA (y-axis) or
PBS-Tween 20 buffer (x-axis). PBS-Tween reports slightly higher NPX-
values for the majority of the 92 proteins.
3.2 Proteins are measurable from the FTA cards
We next compared liquid plasma samples with plasma
applied to the indicating FTA elute micro card™ and stored
for either 24 h or 72 h. One punch from each FTA card was
eluted in 20 μl PBS-Tween 20 buffer and analysed using the
Proseek Multiplex Oncology I v2 panel. As expected from
the elution protocol, the plasma sampled and applied to the
FTA showed generally lower protein amounts than the
liquid plasma samples. In total, 87 of the 92 proteins in the
panel were detected in all liquid plasma samples and 56
and 52 proteins were detected in the samples on FTA cards





24 h (% of
samples over
LOD)
72 h (% of
samples over
LOD)
IL-8 100% 100% 100%
VEGF-A 100% 100% 100%
AM 100% 100% 100%
GDF-15 100% 100% 100%
PlGF 100% 100% 100%
CSF-1 100% 100% 100%
CSTB 100% 100% 100%
MCP-1 100% 100% 100%
KLK6 100% 100% 100%
TRAIL-R2 100% 100% 100%
LAP-TGF-beta-1 100% 100% 100%
TF 100% 100% 100%
TNF-R1 100% 100% 100%
PDGF-subunit-B 100% 100% 100%
PARK7 100% 100% 100%
CXCL11 100% 100% 100%
VE-statin 100% 100% 100%
IL-7 100% 100% 100%
SCF 100% 100% 100%
CXCL9 100% 100% 100%
TNF-R2 100% 100% 100%
TNFSF14 100% 100% 100%
GH 100% 100% 100%
FasL 100% 100% 100%
FAS 100% 100% 100%
CCL19 100% 100% 100%
EMMPRIN 100% 100% 100%
CXCL10 100% 100% 100%
Ep-CAM 100% 100% 100%
HGF 100% 100% 100%
LITAF 100% 100% 100%
CXCL5 100% 100% 100%
MK 100% 100% 100%
U-PAR 100% 100% 100%
CDH3 100% 100% 100%
LYN 100% 100% 100%
Flt3L 100% 100% 100%
HB-EGF 100% 100% 100%
CD69 100% 100% 100%
TR-AP 100% 100% 100%
CDKN1A 100% 100% 100%
REG-4 100% 100% 100%
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24 h (% of
samples over
LOD)
72 h (% of
samples over
LOD)
VEGF-D 100% 100% 100%
HE4 100% 100% 100%
CXCL13 100% 100% 100%
CA-125 100% 100% 100%
PRSS8 100% 100% 100%
PECAM-1 100% 100% 100%
FR-alpha 100% 100% 100%
TIE2 100% 100% 80%
MIC-A 100% 100% 80%
IL-6 100% 100% 60%
ICOSLG 100% 100% 60%
FS 100% 100% 60%
NTRK3 100% 100% 20%
ILT-3 100% 80% 80%
VEGFR-2 100% 80% 80%
ITGA1 100% 80% 80%
ErbB3-HER3 100% 60% 80%
MIA 100% 60% 80%
PTPN22 100% 60% 60%
SELE 100% 60% 40%
FUR 100% 60% 40%
AR 100% 60% 20%
eIF-4B 100% 40% 40%
EZR 100% 40% 20%
PRL 100% 40% 20%
IL-12 100% 20% 40%
MMP-1 100% 20% 40%
ErbB2-HER2 100% 20% 40%
TNFRSF4 100% 20% 40%
IL-6RA 100% 20% 20%
BAFF 100% 20% 20%
ErbB4-HER4 100% 20% 20%
NEMO 100% 20% 20%
FADD 100% 20% 0%
IFN-gamma 100% 20% 0%
VIM 100% 0% 40%
CASP-3 100% 0% 20%
CD40-L 100% 0% 0%
IL-1ra 100% 0% 0%
hK11 100% 0% 0%
CAIX 100% 0% 0%





24 h (% of
samples over
LOD)
72 h (% of
samples over
LOD)
EGFR 100% 0% 0%
THPO 100% 0% 0%
IL-17RB 100% 0% 0%
CEA 80% 20% 20%
MYD88 80% 0% 20%
EPO 80% 0% 0%
IL-2 60% 80% 100%
TNF 40% 100% 100%
Table 1. List of proteins and percentage of samples over limit of detection
(LOD) for each protein when using liquid plasma (left column) plasma on
indicating FTA elute micro card™ stored for 24h (middle column) and 72h
(right column)
The correlation between all observations for all proteins
between 24 h and 72 h was high (Spearman’s rho, R2=0.89,
p-value < 2.2e-16) (Figure 2). In a per-protein analysis,
replacing values below the limit of detection with protein
specific LOD-values, five proteins (CSF-1, NTRK3,
ICOSLG, SCF and PECAM-1) were found to have nomi‐
nally significant differences between the two time-points
(p < 0.05, Wilcox test). None of these associations remained
significant after multiple hypothesis corrections. Only two
proteins showed a mean difference of more than 1 NPX unit
between samples stored for 24 h and 72 h (CSF-1 and TNF-
R1, both of which had lower NPX values at 72 h).
Figure 2. Correlation between NPX values for all observations with
measurements above the limit of detection at two time-points from cervico-
vaginal fluid samples stored on FTA cards for 24 h (x-axis) and 72 h (y-axis),
Spearman’s rho, R2=0.89, p-value < 2.2e-16
3.3 Washing optimization
There was a large overlap between the proteins that were
detectable in liquid plasma and on the FTA cards. Only six
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proteins were detectable in liquid plasma and on FTA cards
stored for 24 h, but not on FTA cards stored for 72 h (Figure
3). Twelve out of 15 plasma samples on the FTA cards did
not pass the Proseek internal controls for incubation,
extension and detection. Nonetheless, 56 of 92 proteins
were detected over LOD in all samples for FTA cards stored
24 h and 51 of 92 proteins were detected in all samples for
FTA cards stored for 72 h. We reasoned that components in
the surface chemistry of the FTA elute cards™ had a
negative effect on the assay.
Figure 3. The overlap in proteins above LOD in 100% of the samples when
analysing liquid plasma (plasma), plasma samples applied to the indicating
FTA elute micro card™ and stored for 24 h (t24) and 72 h (t72) prior to
analysis
In order to reduce the problem regarding failed internal
controls, we tested three different protocols for washing
punches prior to protein elution. One punch from each of
28 indicating FTA elute micro cards™ with a vaginal fluid
sample was analysed using one of three different protocols:
I) no wash prior to elution; II) 1 x 5 min. wash in 100 μl
water; III) 2 x 5 min. wash in 100 μl water. Samples were
then eluted in 20 μl PBS-Tween 20 buffer and analysed
using the Proseek Multiplex Oncology I v2 panel.
With method I (no wash), eight samples showed signs of
inhibition of internal controls, compared to one sample
with method II and zero samples with method III. In total,
57 of 92 proteins had levels over LOD in all 28 samples
using method I and 73 proteins were detected in 80% of the
samples. With method II, 29 of 92 proteins were detectable
in all 28 samples and 56 proteins were detected in 80% of
the samples. With method III, 21 of 92 proteins had levels
over LOD in all 28 samples and 45 proteins were detected
in 80% of the samples. The number of proteins detected
using the different extraction protocols as a function of the
fraction of individuals with protein levels over LOD is
shown in Figure 4.
3.4 Detectable proteins remain stable on the FTA-cards
The 28 samples were stored for up to 29 months. No
significant effect of storage time on protein amounts was
observed using Bonferroni correction (p > 0.065). With FDR
correction, 19 proteins showed an effect due to storage time
(p < 0.05). The urokinase plasminogen activator surface
receptor (UPAR) protein had the largest difference between
samples stored for one month and samples stored for 29
months, with a mean difference of 3.59 NPX (Supplemen‐
tary Table S1).
3.5 Adding more material does not improve detectability
The additional wash improved the analysis, but may also
have resulted in loss of protein. We therefore investigated
whether increasing the input material, i.e., the number of
punches from a sample, would result in higher protein
amounts. To this end one, two, three or four punches were
obtained from an FTA card with CVF sample from five
women and washed for 2 x 5 min. in 100 μl water (method
III), eluted in a 20 μl PBS-Tween 20 buffer and analysed
using the Proseek Multiplex Oncology I v2 panel. The
samples using one punch passed all the assay controls,
while the samples using two punches or more did not pass
the incubation control. Extension and detection controls
were not affected, regardless of the number of punches
used.
Independent of the number of punches used, roughly 50%
of proteins in the panel showed levels above the LOD in
100% of the women (47/92 with one punch, 47/92 with two
punches, 46/92 with three punches and 46/92 with four
punches). When considering proteins that were measura‐
ble in more than 50% of individuals, 62 and 58 proteins
were above LOD, using one and four punches, respectively.
Thus, increasing the number of punches did not increase
the number of proteins to a level above the LOD when using
the presently used wash and elusion protocol.
Figure 4. The number of proteins detected over limit of detection (LOD) for
the three washing methods as a function of the percentage of samples
studied with a NPX value over the LOD
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3.6 Comparison with liquid cytology samples
For comparison we also investigated samples collected
with the procedure used in liquid-based cytology (Thin‐
Prep transport solution). A total of 28 cytology samples
were analysed using the Proseek Multiplex Oncology I v2
panel. Two of the samples did not pass the internal assay
controls and were removed from the analysis. Only seven
proteins were above the LOD in 100% of the 26 cytology
samples, compared to 21 proteins that were above the LOD










IL-8 100% IL-8 100%
VEGF-A 100% VEGF-A 100%
AM 100% IL-1ra 100%
PlGF 100% CSTB 100%
EZR 100% U-PAR 100%
IL-1ra 100% HE4 100%
CSTB 100% PRSS8 100%
MCP-1 100% MCP-1 96%
TNF-R1 100% TNF-R1 96%
PARK7 100% CEA 96%
FADD 100% EZR 92%
FAS 100% hK11 92%
EMMPRIN 100% Ep-CAM 92%
LITAF 100% CXCL5 92%
CASP-3 100% TF 88%
CDKN1A 100% FAS 88%
TGF-alpha 100% EMMPRIN 88%
HE4 100% CASP-3 88%
eIF-4B 100% FR-alpha 88%
CA-125 100% GDF-15 85%
PRSS8 100% MK 85%
GDF-15 96% TGF-alpha 85%
TF 96% CXCL13 85%
CXCL9 96% VIM 85%
PTPN22 96% PlGF 81%
CXCL10 96% IL-6 81%
CXCL5 96% CXCL10 77%
MK 96% HGF 77%
U-PAR 96% AR 77%
LYN 96% CXCL9 73%










CEA 96% TNF-R2 65%
FUR 93% TR-AP 65%
Ep-CAM 93% KLK6 62%
AR 93% TRAIL-R2 62%
NEMO 93% FADD 62%
KLK6 89% LITAF 62%
hK11 89% NEMO 62%
ErbB3-HER3 89% eIF-4B 62%







FasL 82% CSF-1 46%
CD69 82% PARK7 46%
VIM 82% FUR 46%
FR-alpha 82% CAIX 42%
HGF 79% ErbB4-HER4 42%
ICOSLG 79% CD69 31%
CSF-1 71% MIC-A 31%
ErbB2-HER2 71% AM 27%
MIC-A 71% ErbB2-HER2 27%
VE-statin 68% Flt3L 27%
CDH3 64% CCL19 23%
Flt3L 57% PTPN22 23%
PECAM-1 57% LYN 23%
CCL19 54% PECAM-1 23%
MYD88 54% SCF 15%
ILT-3 46% HB-EGF 15%




TNF 39% TNFRSF4 12%
IL-7 36% IL-12 8%
TNFSF14 36% FasL 8%
ErbB4-HER4 36% MYD88 8%
ITGA1 36% MIA 8%
TRAIL-R2 32% CDKN1A 8%
CXCL11 32% EGFR 8%
SCF 21% ITGA1 8%
FS 21% FS 8%
REG-4 18% ILT-3 4%
HB-EGF 14% TIE2 4%














TIE2 7% IL-2 4%
BAFF 7% IL-7 4%
MIA 7% IL-6RA 4%
TNFRSF4 7% MMP-1 4%
TR-AP 7% TNFSF14 4%
THPO 7% GH 4%
NTRK3 7% CDH3 4%
SELE 4% REG-4 4%
IL-12 4% VEGF-D 4%
PRL 4% IL-17RB 4%
GH 4% CD40-L 0%
CAIX 4% SELE 0%
EGFR 4% EPO 0%
CD40-L 0% VE-statin 0%
EPO 0% PRL 0%
IL-2 0% TNF 0%
IL-6RA 0% ICOSLG 0%
VEGFR-2 0% VEGFR-2 0%
IFN-gamma 0% IFN-gamma 0%
VEGF-D 0% THPO 0%
IL-17RB 0% NTRK3 0%
Table 2. List of proteins and percentage of samples over the limit of detection
(LOD) among the indicating FTA elute micro card™ samples (left column)
and the Liguid-based cytology samples (right column); 2 of the 28 Liguid-
based cytology samples did not pass the quality controls and were excluded.
7 proteins were detected in all 26 Liguid-based cytology samples, compared
to 21 proteins that were detected in the 28 FTA samples.
4. Discussion
This study shows that plasma and cervico-vaginal fluid
samples applied to the indicating FTA elute micro card™
are amendable to protein analysis. The PBS-Tween (0.05 %)
elution is the preferable elution buffer. The majority of
proteins in the Proseek Multiplex Oncology I v2 panel that
were detectable in liquid plasma were also above LOD in
samples applied to the indicating FTA elute micro card™.
The NPX values were generally lower in the FTA card
samples, although some proteins showed high NPX values.
This was to some extent expected because of the elution
process, since for FTA card samples, the 10 μl of plasma in
a punch was eluted in a 20 μl of buffer, resulting in half of
the concentration of proteins entering the assay, compared
to the liquid plasma samples.
Our comparison of washing methods showed that al‐
though extensive washing may results in a loss of protein,
adding a second wash to the punches from FTA cards
reduced the number of samples that did not pass the
internal controls. The results showed that the proteins on
the FTA card appear stable. The protein profile in the
vaginal fluid samples on FTA cards from 28 women stored
for up to two years showed an effect on 19 proteins, with
FDR correction (p < 0.05); however, this effect was not seen
using Bonferroni correction (p > 0.065). We also studied
whether the number of proteins above LOD detected in the
FTA card samples could be increased by adding more
starting material, i.e., more punches in the washing and
elution steps. However, this did not result in additional
proteins appearing above LOD, but only increased the
number of samples failing internal control. An alternative
would be to use a protocol that selectively removes
inhibitors from the FTA cards' surface prior to the elution
of the proteins. The liquid cytology samples showed a
slightly higher abundance of some proteins compared to
samples from the indicating FTA elute micro card™, but
the number of proteins with levels above LOD was higher
for the FTA cards. The lower number of detectable proteins
in the liquid cytology samples may have been due to the
procedure for sample collection and storage, and in
particular, the substantial dilution of the original sample in
the transport solution.
Our study demonstrates the feasibility of measuring
proteins from vaginal fluid and plasma collected onto the
indicating FTA elute micro card™. This opens up the
possibility of studying both DNA, RNA and protein
biomarkers in a single sample applied to the indicating FTA
elute micro card™. The indicating FTA elute micro card™
is extremely suitable where biobanking is concerned, since
these cards can be stored at room temperature and do not
require large storage space or the subzero conditions
needed for liquid cytology samples.
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